Drug Trial Radar · NCT03392467
PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants
Last checked: Nov 20, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Aug 13, 2018
Primary completion
Jan 9, 2024
Study completion Oct 18, 2024
Sponsor
- Lead sponsor
- Medipost Co Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 13 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of PNEUMOSTEM® for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia (Severe BPD) in Premature Infants. Half of subjects will receive PNEUMOSTEM, while the other half will receive a placebo.
Conditions
- Severe Bronchopulmonary Dysplasia
Interventions
PNEUMOSTEMBiological
human umbilical cord blood-derived mesenchymal stem cells
PlaceboOther
normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects who have severe BPD or are deadTime frame: 36 weeks postmenstrual age (PMA)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Asan medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.